Values First Advisors’s Aimmune Therapeutics AIMT Stock Holding History

Values First Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-6,054	Closed	-$209K	–	148
2020 Q3	$209K	Sell	6,054 -28,908	-83%	-$616K	0.19%	130
2020 Q2	$584K	Buy	34,962 +7,920	+29%	+$134K	0.58%	59
2020 Q1	$390K	Buy	27,042 +1,301	+5%	+$33.3K	0.47%	69
2019 Q4	$862K	Buy	+25,741	New	+$720K	0.83%	47

Values First Advisors's AIMT Position: Q4 2020 in Review

Values First Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 6,054 shares — an estimated $209K sold.

Values First Advisors first reported a position in AIMT in Q4 2019 and held it in 4 quarters. The position peaked at $862K in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Values First Advisors reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Values First Advisors sold 6,054 Aimmune Therapeutics shares in Q4 2020, an estimated $209K.
Values First Advisors first reported a position in Aimmune Therapeutics in Q4 2019 and held it in 4 quarters.
Values First Advisors's Aimmune Therapeutics position peaked at $862K in Q4 2019.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Values First Advisors's 13F filing for Q4 2020, filed 15 Nov 2022.